{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:57:24Z","timestamp":1792112244982,"version":"4.4.0"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Antipsychotic medications, often prescribed for delirium in intensive care units (ICUs), may contribute to QTc interval prolongation.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether antipsychotics increase the QTc interval in patients with delirium in the ICU.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n An a priori analysis of a randomized clinical trial in medical\/surgical ICUs within 16 centers across the US was conducted. Participants included adults with delirium in the ICU with baseline QTc interval less than 550 ms. The study was conducted from December 2011 to August 2017. Data analysis was performed from April 25 to August 18, 2021.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Patients were randomized 1:1:1 to intravenous haloperidol, ziprasidone, or saline placebo administered twice daily until resolution of delirium, ICU discharge, or 14 days.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Twelve-lead electrocardiograms were used to measure baseline QTc before study drug initiation and telemetry was used to measure QTc before each subsequent dose of study drug. Unadjusted day-to-day changes in QTc were calculated and multivariable proportional odds regression was used to estimate the effects of antipsychotics vs placebo on next-day maximum QTc interval, adjusting for prespecified baseline covariates and potential interactions with sex. Safety end points, including the occurrence of torsade de pointes, were evaluated. All analyses were conducted based on the intention to treat principle.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 566 patients were randomized to haloperidol (n\u2009=\u2009192), ziprasidone (n\u2009=\u2009190), or placebo (n\u2009=\u2009184). Median age was 60.1 (IQR, 51.4-68.7) years; 323 were men (57%). Baseline median QTc intervals across the groups were similar: haloperidol, 458.0 (IQR, 432.0-479.0) ms; ziprasidone, 451.0 (IQR, 424.0-472.0) ms; and placebo, 452.0 (IQR, 432.0-472.0) ms. From day 1 to day 2, median QTc changed minimally: haloperidol, \u22121.0 (IQR, \u221228.0 to 15.0) ms; ziprasidone, 0 (IQR, \u221223.0 to 20.0) ms; and placebo, \u22123.5 (IQR, \u221224.8 to 17.0) ms. Compared with placebo, neither haloperidol (odds ratio [OR], 0.95; 95% CI, 0.66-1.37;\n P<\/jats:italic>\n \u2009=\u2009.78) nor ziprasidone (OR, 1.09; 95% CI, 0.75-1.57;\n P<\/jats:italic>\n \u2009=\u2009.78) was associated with next-day QTc intervals. Effects were not significantly modified by sex (\n P<\/jats:italic>\n \u2009=\u2009.41 for interaction). There were 2 occurrences of nonfatal torsade de pointes, both in the haloperidol group. Neither was associated with study drug administration.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The findings of this trial suggest that daily QTc interval monitoring during antipsychotic use may have limited value in patients in the ICU with normal baseline QTc and few risk factors for QTc prolongation.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT01211522<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.52034","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T11:32:05Z","timestamp":1705923125000},"page":"e2352034","source":"Crossref","is-referenced-by-count":21,"title":["Antipsychotics and the QTc Interval During Delirium in the Intensive Care Unit"],"prefix":"10.1001","volume":"7","author":[{"given":"Joanna L.","family":"Stollings","sequence":"first","affiliation":[{"name":"Critical Illness, Brain Dysfunction, and Survivorship Center, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina S.","family":"Boncyk","sequence":"additional","affiliation":[{"name":"Critical Illness, Brain Dysfunction, and Survivorship Center, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline I.","family":"Birdrow","sequence":"additional","affiliation":[{"name":"Critical Illness, Brain Dysfunction, and Survivorship Center, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencong","family":"Chen","sequence":"additional","affiliation":[{"name":"Critical Illness, Brain Dysfunction, and Survivorship Center, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rameela","family":"Raman","sequence":"additional","affiliation":[{"name":"Critical Illness, Brain Dysfunction, and Survivorship Center, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak K.","family":"Gupta","sequence":"additional","affiliation":[{"name":"Center for Health Services Research, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Vanderbilt Heart Imaging Core Lab, Vanderbilt Translational and Clinical Cardiovascular Research Center, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan M.","family":"Roden","sequence":"additional","affiliation":[{"name":"Department of Medicine, Departments of Pharmacology and Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika L.","family":"Rivera","sequence":"additional","affiliation":[{"name":"Section of Surgical Sciences, Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Surgical Service, Department of Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia W.","family":"Maiga","sequence":"additional","affiliation":[{"name":"Critical Illness, Brain Dysfunction, and Survivorship Center, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Section of Surgical Sciences, Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan","family":"Rakhit","sequence":"additional","affiliation":[{"name":"Critical Illness, Brain Dysfunction, and Survivorship Center, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Section of Surgical Sciences, Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik P.","family":"Pandharipande","sequence":"additional","affiliation":[{"name":"Critical Illness, Brain Dysfunction, and Survivorship Center, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Center for Health Services Research, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Anesthesia Service, Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville"},{"name":"Geriatric Research Education and Clinical Center, Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Wesley","family":"Ely","sequence":"additional","affiliation":[{"name":"Critical Illness, Brain Dysfunction, and Survivorship Center, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Center for Health Services Research, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Geriatric Research Education and Clinical Center, Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville"},{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Girard","sequence":"additional","affiliation":[{"name":"Critical Illness, Brain Dysfunction, and Survivorship Center, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Center for Research, Investigation, and Systems Modeling of Acute Illness in the Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur B.","family":"Patel","sequence":"additional","affiliation":[{"name":"Critical Illness, Brain Dysfunction, and Survivorship Center, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Center for Health Services Research, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Section of Surgical Sciences, Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Surgical Service, Department of Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, Tennessee"},{"name":"Geriatric Research Education and Clinical Center, Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"issue":"3","key":"zoi231524r1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death.","volume":"360","author":"Ray","year":"2009","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi231524r2","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/archpsyc.58.12.1161","article-title":"Antipsychotics and the risk of sudden cardiac death.","volume":"58","author":"Ray","year":"2001","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"zoi231524r3","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.","volume":"158","author":"Glassman","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"9209","key":"zoi231524r4","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S0140-6736(00)02035-3","article-title":"QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients.","volume":"355","author":"Reilly","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"zoi231524r5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition.","volume":"24","author":"Harrigan","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"zoi231524r6","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1001\/archinte.164.12.1293","article-title":"Antipsychotics and the risk of sudden cardiac death.","volume":"164","author":"Straus","year":"2004","journal-title":"Arch Intern Med"},{"issue":"6","key":"zoi231524r7","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1001\/archinte.165.6.696","article-title":"Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest.","volume":"165","author":"Liperoti","year":"2005","journal-title":"Arch Intern Med"},{"issue":"3","key":"zoi231524r8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/00004714-200106000-00002","article-title":"The association between intravenous haloperidol and prolonged QT interval.","volume":"21","author":"Hatta","year":"2001","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"zoi231524r9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ccell.2006.01.007","article-title":"Practice standards for ECG monitoring in hospital settings: executive summary and guide for implementation.","volume":"18","author":"Drew","year":"2006","journal-title":"Crit Care Nurs Clin North Am"},{"issue":"8","key":"zoi231524r10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2165\/00002018-200124080-00002","article-title":"Is gender a risk factor for adverse drug reactions? the example of drug-induced long QT syndrome.","volume":"24","author":"Drici","year":"2001","journal-title":"Drug Saf"},{"issue":"20","key":"zoi231524r11","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jama.280.20.1774","article-title":"Cardiac actions of erythromycin: influence of female sex.","volume":"280","author":"Drici","year":"1998","journal-title":"JAMA"},{"issue":"5","key":"zoi231524r12","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1089\/jwh.1998.7.547","article-title":"Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence.","volume":"7","author":"Ebert","year":"1998","journal-title":"J Womens Health"},{"issue":"21","key":"zoi231524r13","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1001\/jama.1993.03510210076031","article-title":"Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.","volume":"270","author":"Makkar","year":"1993","journal-title":"JAMA"},{"issue":"3","key":"zoi231524r14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/acp.2005.111.issue-3","article-title":"Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors.","volume":"111","author":"Justo","year":"2005","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"zoi231524r15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ejim.2005.12.003","article-title":"Torsades de pointes induced by antibiotics.","volume":"17","author":"Justo","year":"2006","journal-title":"Eur J Intern Med"},{"issue":"6","key":"zoi231524r16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/myc.2006.49.issue-6","article-title":"Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports.","volume":"49","author":"Justo","year":"2006","journal-title":"Mycoses"},{"issue":"2","key":"zoi231524r17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1086\/cid.2002.35.issue-2","article-title":"Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System.","volume":"35","author":"Shaffer","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"5","key":"zoi231524r18","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/pace.1998.21.issue-5","article-title":"Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study.","volume":"21","author":"Houltz","year":"1998","journal-title":"Pacing Clin Electrophysiol"},{"issue":"5","key":"zoi231524r19","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.amjcard.2007.04.020","article-title":"Risk factors and predictors of torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving dofetilide.","volume":"100","author":"Pedersen","year":"2007","journal-title":"Am J Cardiol"},{"issue":"6","key":"zoi231524r20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/pds.v17:6","article-title":"Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.","volume":"17","author":"Astr\u00f6m-Lilja","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"zoi231524r21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1113\/jphysiol.1920.sp001881","article-title":"The time relations of the blood-pressure changes after excision of the adrenal glands, with some observations on blood volume changes.","volume":"53","author":"Bazett","year":"1920","journal-title":"J Physiol"},{"issue":"1","key":"zoi231524r23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s13311-011-0102-9","article-title":"Pharmacological and nonpharmacological management of delirium in critically ill patients.","volume":"9","author":"Hipp","year":"2012","journal-title":"Neurotherapeutics"},{"issue":"2","key":"zoi231524r24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/CCM.0b013e3181b9e302","article-title":"Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.","volume":"38","author":"Devlin","year":"2010","journal-title":"Crit Care Med"},{"key":"zoi231524r25","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/1471-244X-13-240","article-title":"Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium.","volume":"13","author":"Yoon","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"26","key":"zoi231524r26","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1808217","article-title":"Haloperidol and ziprasidone for treatment of delirium in critical illness.","volume":"379","author":"Girard","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"zoi231524r27","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2211868","article-title":"Haloperidol for the treatment of delirium in ICU patients.","volume":"387","author":"Andersen-Ranberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi231524r28","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1001\/jama.2018.0160","article-title":"Effect of haloperidol on survival among critically ill adults with a high risk of delirium: the REDUCE randomized clinical trial.","volume":"319","author":"van den Boogaard","year":"2018","journal-title":"JAMA"},{"issue":"11","key":"zoi231524r29","doi-asserted-by":"publisher","first-page":"e1111","DOI":"10.1097\/CCM.0000000000002640","article-title":"Worldwide survey of the \u201cAssessing Pain, Both Spontaneous Awakening and Breathing Trials, Choice of Drugs, Delirium Monitoring\/Management, Early Exercise\/Mobility, and Family Empowerment\u201d (ABCDEF) bundle.","volume":"45","author":"Morandi","year":"2017","journal-title":"Crit Care Med"},{"issue":"2","key":"zoi231524r30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.psym.2017.10.009","article-title":"QT prolongation, torsades de pointes, and psychotropic medications: a 5-year update.","volume":"59","author":"Beach","year":"2018","journal-title":"Psychosomatics"},{"issue":"7","key":"zoi231524r31","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1097\/00003246-200107000-00012","article-title":"Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU).","volume":"29","author":"Ely","year":"2001","journal-title":"Crit Care Med"},{"issue":"1","key":"zoi231524r32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/CCM.0b013e3182783b72","article-title":"Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit.","volume":"41","author":"Barr","year":"2013","journal-title":"Crit Care Med"},{"issue":"6","key":"zoi231524r33","doi-asserted-by":"publisher","first-page":"17B","DOI":"10.1016\/0002-9149(93)90035-B","article-title":"Rate-corrected QT interval: techniques and limitations.","volume":"72","author":"Funck-Brentano","year":"1993","journal-title":"Am J Cardiol"},{"issue":"1","key":"zoi231524r34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S1056-8719(03)00008-X","article-title":"How to correct the QT interval for the effects of heart rate in clinical studies.","volume":"48","author":"Davey","year":"2002","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"2","key":"zoi231524r35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"2","key":"zoi231524r36","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0002-9149(97)00888-6","article-title":"Torsades de pointes associated with intravenous haloperidol in critically ill patients.","volume":"81","author":"Sharma","year":"1998","journal-title":"Am J Cardiol"},{"issue":"4","key":"zoi231524r37","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/00131746-200407000-00003","article-title":"No significant QTc interval changes with high-dose ziprasidone: a case series.","volume":"10","author":"Levy","year":"2004","journal-title":"J Psychiatr Pract"},{"issue":"3","key":"zoi231524r38","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.clinthera.2010.03.003","article-title":"Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.","volume":"32","author":"Miceli","year":"2010","journal-title":"Clin Ther"},{"issue":"8","key":"zoi231524r39","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.","volume":"121","author":"Drew","year":"2010","journal-title":"Circulation"},{"issue":"5","key":"zoi231524r40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.7326\/0003-4819-119-5-199309010-00007","article-title":"Torsade de pointes associated with the use of intravenous haloperidol.","volume":"119","author":"Wilt","year":"1993","journal-title":"Ann Intern Med"},{"issue":"5","key":"zoi231524r41","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jamainternmed.2020.0148","article-title":"Association of QT-prolonging medications with risk of autopsy-defined causes of sudden death.","volume":"180","author":"Simpson","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"3","key":"zoi231524r42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/JCP.0000000000001373","article-title":"How to estimate QT interval in patients with left or right bundle branch block: a systematic review.","volume":"41","author":"Fredholm","year":"2021","journal-title":"J Clin Psychopharmacol"},{"issue":"16","key":"zoi231524r43","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1001\/jama.289.16.2120","article-title":"What clinicians should know about the QT interval.","volume":"289","author":"Al-Khatib","year":"2003","journal-title":"JAMA"},{"key":"zoi231524r22","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2814118\/stollings_2024_oi_231524_1705006722.28102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T11:32:11Z","timestamp":1705923131000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2814118"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.52034","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]}}}